<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04792281</url>
  </required_header>
  <id_info>
    <org_study_id>MP-33-2020-2674</org_study_id>
    <nct_id>NCT04792281</nct_id>
  </id_info>
  <brief_title>Impact of FDG-PET/CT on Management of Patients With Native Valve Infective Endocarditis</brief_title>
  <acronym>PET-NAVIE</acronym>
  <official_title>Impact of FDG-PET/CT on Management of Patients With Native Valve Infective Endocarditis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montreal Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montreal Heart Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study is a multicentric prospective observational cohort study of patients with&#xD;
      suspected NVE. The study population includes those with Possible IE according to the modified&#xD;
      Duke criteria and investigated at one of the 6 participating sites which include 2 cardiac&#xD;
      centers, the MHI and the IUCPQ, as well as 4 tertiary care centers, the Jewish General&#xD;
      Hospital , the McGill University Health Centre and the CHUS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 30, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with Possible IE that will be appropriately reclassified</measure>
    <time_frame>3 months</time_frame>
    <description>Proportion of patients with Possible IE that will be appropriately reclassified as Definite IE by the addition of FDG-PET to the Duke criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity, specificity, and accuracy of FDG-PET for the detection of NVE</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity, specificity, and accuracy of the Duke criteria with FDG-PET for detection of NVESensitivity, specificity, and accuracy of the Duke criteria with FDG-PET for detection of NVE</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity, specificity, and accuracy of the Duke criteria with FDG-PET but excluding TEE for the detection of NVE</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in maximal standardized uptake value (SUVmax) between infected and non-infected valves</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences target-to-background ratio (TBR) between infected and non-infected valves</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in whom a TEE was not necessary to diagnose NVE through the addition of FDG-PET</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with final diagnosis of IE with septic emboli detected on whole body FDGPET</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in the rate of sub-optimal suppression protocol between males and females</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with incidental cancer identified on FDG-PET</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlation between the diagnostic accuracy and available demographic, technical, and clinical factors</measure>
    <time_frame>3 months</time_frame>
    <description>Correlation between the diagnostic accuracy (false-negative/false-positive studies versus truenegative/true-positive) and the available demographic and clinical factors (age, sex, duration of antibiotherapy, blood glucose, CRP, history of renal failure, history of malignancy, history of diabetes, chronic liver disease, time since onset of symptoms, and quality of myocardial suppression) as well as camera system (analog vs digital)</description>
  </other_outcome>
  <other_outcome>
    <measure>Difference in the area under the curve (c-statistic) of the Duke criteria with TEE but excluding FDG-PET, with TEE and FDG-PET, and with FDG-PET but excluding TEE</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Differences in sensitivity, specificity, and accuracy of FDG-PET with and without respiratory and ECG-gated acquisitions</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">97</enrollment>
  <condition>Infective Endocarditis</condition>
  <condition>Native Valve Endocarditis</condition>
  <arm_group>
    <arm_group_label>Patients with suspected native valve endocarditis</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study population includes those with Possible IE according to the modified Duke&#xD;
        criteria and investigated at one of the 5 participating sites&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older, capable to provide informed consent;&#xD;
&#xD;
          -  Referred for a FDG-PET/CT study&#xD;
&#xD;
          -  Classified as having Possible IE prior to FDG-PET/CT imaging;&#xD;
&#xD;
          -  Patients must be able to tolerate the physical/logistical requirements of a PET/CT&#xD;
             scan.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with prosthetic cardiac valve and/or CIED;&#xD;
&#xD;
          -  Pregnant or breastfeeding female;&#xD;
&#xD;
          -  Body mass index &gt; 45 kg/m2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gad Abikhzer</last_name>
      <phone>514-340-8222</phone>
      <email>gad101@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anthony Ciarallo</last_name>
      <phone>514-934-1934</phone>
      <email>Anthony.Ciarallo.med@ssss.gouv.qc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Universite de Montreal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Juneau</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3l 3c1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthieu Pelletier-Galarneau</last_name>
      <phone>5143763330</phone>
      <phone_ext>4418</phone_ext>
      <email>matthieu.pelletier-galarneau@icm-mhi.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Universite de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H5H3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Etienne Rousseau</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Institute of Cardiology and Respirology of Quebec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Francois Sarrazin</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 5, 2021</study_first_submitted>
  <study_first_submitted_qc>March 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>March 26, 2021</last_update_submitted>
  <last_update_submitted_qc>March 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montreal Heart Institute</investigator_affiliation>
    <investigator_full_name>Matthieu Pelletier-Galarneau, MD MSc</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>PET/CT</keyword>
  <keyword>FDG</keyword>
  <keyword>Duke Criteria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocarditis, Bacterial</mesh_term>
    <mesh_term>Endocarditis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

